You are not currently logged in.
Access JSTOR through your library or other institution:
Risk Factors for Fluconazole-Resistant Candidiasis in Human Immunodeficiency Virus-Infected Patients
Janine R. Maenza, Jeanne C. Keruly, Richard D. Moore, Richard E. Chaisson, William G. Merz and Joel E. Gallant
The Journal of Infectious Diseases
Vol. 173, No. 1 (Jan., 1996), pp. 219-225
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30127966
Page Count: 7
You can always find the topics here!Topics: Candidiasis, Azoles, Oral candidiasis, Antifungals, AIDS, Candida albicans, Predisposing factors, Dosage, HIV, Esophagitis
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
In a case-control study to identify risk factors for fluconazole-resistant oroesophageal candidiasis in human immunodeficiency virus-infected patients, 25 patients with clinical and in vitro fluconazole-resistant candidiasis were paired with controls who had treatment-responsive candidiasis and who had been observed for similar time periods. After their first episode of candidiasis, patients who later developed fluconazole resistance had more treated episodes than did matched controls (cases, 3.1; controls, 1.8; P = .004), lower median CD4 cell counts (11/$mm^3$ vs. 71/$mm^3$; P = .004), and greater median durations of all antifungal therapy (419 vs. 118 days; P <.001) and of systemic azole therapy (272 vs. 14 days; P <.001). When paired with a second set of controls matched by CD4 cell count as well as first diagnosis of candidiasis, cases continued to show greater median exposure to azoles (272 vs. 88 days; P = .005). These data indicate that advanced immunosuppression and exposure to oral azoles are risk factors for the development of fluconazole resistance.
The Journal of Infectious Diseases © 1996 Oxford University Press